DEA And Marijuana Rescheduling Opponents File Final Briefs In Hearing Ahead Of Judge's Decision

A final set of briefs was filed by opponents in the DEA marijuana rescheduling hearing, leaving patients, growers and investors uncertain about the future legal status of cannabis. The pending judicial decision could alter how the drug is classified, affect medical access, and reshape market dynamics. Stakeholders anticipate that the outcome may either tighten controls or maintain the current schedule, influencing everyday buying and prescribing practices.

Critics argue the government has not met its evidentiary burden, as noted by reflector.com, and a former DEA administrator warned of safety risks in The Globe and Mail. The American Medical Association, quoted in Healio and Cannabis Wire, is pushing the FDA to apply the same scrutiny to botanical products as to traditional drugs. Evidence cited includes the AMA’s formal request to the FDA, the former administrator’s alarm, and the procedural filings now on the record, reported by Marijuana Moment.

With the judge’s ruling still pending, observers ask whether the court will endorse the rescheduling or uphold the current classification, a question that will shape policy and industry for years to come.